Interleukin

Biotechnology

Biology

Aldesleukin

Interleukin 15

T cell

Transplantation

Immunology

In vivo

Immune system

Cytokine

Internal medicine

Pharmacology

Medicine

Blood

Key Points Single-agent IL-15/IL-15Rα-Fc (ALT-803) therapy was well tolerated and resulted in clinical responses in patients who relapsed post-HCT. First-in-human use of ALT-803 promoted NK and CD8+ T-cell expansion and activation in vivo without stimulating regulatory T cells.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation